# Boehringer Ingelheim for UK Healthcare Professionals

Your partner in daily practice and patient consultation

## Diseases and Products

### Asthma

A disease of the airways

[See more](https://pro.boehringer-ingelheim.com/uk/resources/respiratory-healthcare-professional-resource/respimat-inhaler/how-would-you-treat-a-severe-asthma-patient/about-severe-asthma "See more")

### CHF

Chronic Heart Failure

[See more](https://pro.boehringer-ingelheim.com/uk/bipdf/empagliflozin-chronic-heart-failure "See more")

### CKD

Chronic Kidney Disease

[See more](https://pro.boehringer-ingelheim.com/uk/bipdf/empagliflozin-chronic-kidney-disease "See more")

### COPD

Chronic Obstructive Pulmonary Disease

[See more](https://pro.boehringer-ingelheim.com/uk/respiratory-hub "See more")

### IPF

Idiopathic Pulmonary Fibrosis

[See more](https://pro.boehringer-ingelheim.com/uk/diseases/idiopathic-pulmonary-fibrosis/overview "See more")

### PPF

Progressive Pulmonary Fibrosis

[See more](https://pro.boehringer-ingelheim.com/uk/diseases/chronic-progressive-fibrotic-ild "See more")

### Stroke

Brain damage due to restricted blood supply to the brain

[See more](https://pro.boehringer-ingelheim.com/uk/products/metalyse-25-mg-tenecteplase "See more")

### Type 2 Diabetes

A metabolic disorder

[See more](https://pro.boehringer-ingelheim.com/uk/type-2-diabetes "See more")

PC-GB-110857 V9 May 2026

#### Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at [www.mhra.gov.uk/yellowcard](https://pro.boehringer-ingelheim.com/uk/external-link?external=https%3A%2F%2Fyellowcard.mhra.gov.uk%2F "www.mhra.gov.uk/yellowcard"). Adverse events should also be reported to Boehringer Ingelheim Drug Safety on [0800 328 1627](tel:0800 328 1627 "0800 328 1627") (freephone).

Please be aware that this website contains promotional information about Boehringer Ingelheim medicines and services. Some of this may not be directly relevant to your scope of practice and it is your own decision whether you choose to view this information.